Register
News and Updates
eMediNexus Coverage from: 
FDA approves first therapy for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura
eMediNexus,  07 February 2019
remove_red_eye 778 Views
#Pathology and Lab Medicine #Pharmacist

1 Read Comments                

The US Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) injection, the first therapy specifically indicated, in combination with plasma exchange and immunosuppressive therapy, for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), a rare and life-threatening disorder that causes blood clotting.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now